Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

311 questions · 316 findings · 105 reviews · Schizophrenia

No studies found 14 · 4.4%GRADE not reported 11 · 3.5%Very low 143 · 45.3%Low 79 · 25%Moderate 66 · 20.9%High 3 · 0.9%

Levomepromazine vs Typical antipsychotics

Withdrawals due to adverse events · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with typical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ medium term ‐ any reason · patients with schizophrenia

It is very uncertain whether levomepromazine changes leaving the study early ‐ medium term ‐ any reason compared with typical antipsychotics (very low certainty).

1 finding from 1 review

Levomepromazine vs Typical antipsychotics

Acceptability of treatment ‐ leaving the study early · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ any reason compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ long term ‐ due to adverse events · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ due to adverse events compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ long term ‐ lost to · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ lost to compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with atypical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Withdrawals due to adverse events · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term

Leaving the study early · patients with schizophrenia

ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

2 findings from 1 review

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher leaving the study early: any reason ‐ when compared with high dose (… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: Any reasons ‐ when compared with ultra low dose (<2 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with ultra low… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: Any reasons ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ When compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: insufficient response ‐ When compared with ultra low dose (<2 mg/day) · patients with schizophrenia

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: insufficient response ‐ When compared with low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: insufficient response ‐ When compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia

ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: insufficient response ‐ When compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: insufficient response ‐ When compared with ultra low dose (<2 mg/day) · patients with schizophrenia

HIGH DOSE (greater than or equal to 10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: insufficient response ‐ When compared with low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia

HIGH DOSE (greater than or equal to 10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review